- Eli Lilly (NYSE:LLY) Q2 Results ($M): Total Revenues: 5,404.8 (+8.6%); Animal Health: 859.8 (+2.3%).
- Net Income: 747.7 (+24.5%); Non-GAAP Net Income: 908.8 (-4.8%); EPS: 0.71 (+26.8%); Non-GAAP EPS: 0.86 (-4.4%).
- Key Product Sales: Humalog: 701.9 (+7.3%); Cialis: 630.5 (+11.0%); Alimta: 607.1 (-8.6%); Forteo: 367.6 (+11.9%); Humulin: 332.3 (+5.0%); Cymbalta: 236.5 (-13.7%); Strattera: 224.6 (+17.1%); Zyprexa: 210.7 (-16.9%); Trulicity: 201.3 (+354.4%); Erbitux: 180.6 (+34.2%); Cyramza: 147.0 (+67.6%); Effient: 135.1 (+4.9%).
-
2016 Guidance: Revenue: $20.6B - 21.1B (unch): EPS: $2.68 - 2.78 (unch); Non-GAAP EPS: $3.50 - 3.60.